αTrop2/αCD3 bispecific protein engager-armed T cells (BATs) exhibit potent antitumor activity against nasopharyngeal carcinoma
Open Access
- 7 May 2026
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 75 (7)
Abstract
Nasopharyngeal carcinoma (NPC) remains a highly aggressive malignancy with poor outcomes in advanced and recurrent disease. Although immune checkpoint inhibitors combined with chemotherapy improve survival, many patients still experience relapse or disease progression. Here, we developed a non-genetically modified cellular immunotherapy based on αTrop2/αCD3 bispecific protein engager-armed T cells (αTrop2/αCD3-BATs), targeting Trop2, which is highly expressed in NPC and minimally expressed in normal tissues. Molecular dynamics simulations supported stable dual binding of the BiPE to Trop2 and CD3ε, consistent with effective immune synapse formation. Functionally, αTrop2/αCD3-BATs exhibited potent, antigen-dependent cytotoxicity against Trop2-positive NPC cell lines (TW01, HK1, and CNE1) in both two-dimensional co-culture and three-dimensional spheroid models while sparing Trop2-negative cells. Target engagement induced robust T cell activation and proliferation, accompanied by increased expression of effector molecules such as FasL and elevated secretion of cytolytic mediators (perforin, granzymes, and granulysin) and pro-inflammatory cytokines (IFN-γ, TNF-α, and IL-2). Collectively, these findings demonstrate that αTrop2/αCD3-BATs mediate potent and selective antitumor activity and support their further preclinical development as an MHC-independent cellular immunotherapy for Trop2-positive NPC.Keywords
Funding Information
- Mahidol University (FF-052/2567)
- Mahidol University
This publication has 55 references indexed in Scilit:
- Bispecific T cell engager-armed T cells targeting integrin ανβ6 exhibit enhanced T cell redirection and antitumor activity in cholangiocarcinomaBiomedicine & Pharmacotherapy, 2024
- Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal CarcinomaJAMA, 2023
- Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1International Immunopharmacology, 2023
- Improvements to the APBS biomolecular solvation software suiteProtein Science, 2017
- Epstein‐Barr virus‐specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinomaCancer, 2017
- Targeting CD138−/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma ImmunityTransplantation and Cellular Therapy, 2016
- Long-Term Outcomes of Early-Stage Nasopharyngeal Carcinoma Patients Treated With Intensity-Modulated Radiotherapy AloneInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Treatment Outcomes After Radiotherapy Alone for Patients With Early-Stage Nasopharyngeal CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Association of immunoescape mechanisms with Epstein‐Barr virus infection in nasopharyngeal carcinomaInternational Journal of Cancer, 2007
- Development and testing of a general amber force fieldJournal of Computational Chemistry, 2004